[go: up one dir, main page]

CL2015001020A1 - Compuestos derivados de 4-carboxamido-isoindolinona, inhibidores selectivos de parp-1; proceso de preparacion; composicion farmaceutica; un metodo in vitro; un producto; y su uso como medicamento con actividad antineoplasica - Google Patents

Compuestos derivados de 4-carboxamido-isoindolinona, inhibidores selectivos de parp-1; proceso de preparacion; composicion farmaceutica; un metodo in vitro; un producto; y su uso como medicamento con actividad antineoplasica

Info

Publication number
CL2015001020A1
CL2015001020A1 CL2015001020A CL2015001020A CL2015001020A1 CL 2015001020 A1 CL2015001020 A1 CL 2015001020A1 CL 2015001020 A CL2015001020 A CL 2015001020A CL 2015001020 A CL2015001020 A CL 2015001020A CL 2015001020 A1 CL2015001020 A1 CL 2015001020A1
Authority
CL
Chile
Prior art keywords
parp
isoindolinone
carboxamido
medicine
pharmaceutical composition
Prior art date
Application number
CL2015001020A
Other languages
English (en)
Inventor
Gianluca Mariano Enrico Papeo
Mikhail Yurievitch Krasavin
Paolo Orsini
Alessandra Scolaro
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47115518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of CL2015001020A1 publication Critical patent/CL2015001020A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CL2015001020A 2012-10-26 2015-04-22 Compuestos derivados de 4-carboxamido-isoindolinona, inhibidores selectivos de parp-1; proceso de preparacion; composicion farmaceutica; un metodo in vitro; un producto; y su uso como medicamento con actividad antineoplasica CL2015001020A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12190130 2012-10-26

Publications (1)

Publication Number Publication Date
CL2015001020A1 true CL2015001020A1 (es) 2015-07-31

Family

ID=47115518

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001020A CL2015001020A1 (es) 2012-10-26 2015-04-22 Compuestos derivados de 4-carboxamido-isoindolinona, inhibidores selectivos de parp-1; proceso de preparacion; composicion farmaceutica; un metodo in vitro; un producto; y su uso como medicamento con actividad antineoplasica

Country Status (18)

Country Link
US (4) US10385018B2 (es)
EP (1) EP2912032B1 (es)
JP (1) JP6314147B2 (es)
KR (1) KR102221199B1 (es)
CN (1) CN104768948B (es)
AU (1) AU2013336725B2 (es)
BR (1) BR112015009130B1 (es)
CA (1) CA2889581C (es)
CL (1) CL2015001020A1 (es)
DK (1) DK2912032T3 (es)
EA (1) EA028506B1 (es)
ES (1) ES2813530T3 (es)
HU (1) HUE051078T2 (es)
MX (1) MX367425B (es)
PL (1) PL2912032T3 (es)
PT (1) PT2912032T (es)
SI (1) SI2912032T1 (es)
WO (1) WO2014064149A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10385018B2 (en) 2012-10-26 2019-08-20 Nerviano Medical Sciences S.R.L. 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors
CN111100116A (zh) * 2019-11-14 2020-05-05 南京大学 一类新型的含甲基吲哚的以吡唑啉为骨架的苯胺衍生物的制备方法及应用
CN111205263A (zh) * 2020-04-22 2020-05-29 北京鑫开元医药科技有限公司 一种双环醇的制备方法及用途
EP4326720A4 (en) 2021-04-19 2025-03-19 Xinthera, Inc. Parp1 inhibitors and uses thereof
KR20250145706A (ko) 2021-10-01 2025-10-13 신테라, 인크. 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도
JP7607841B1 (ja) 2022-01-21 2024-12-27 シンセラ， インコーポレイテッド Ｐａｒｐ１阻害薬及びその使用
CA3250945A1 (en) 2022-04-28 2023-11-02 Xinthera, Inc. TRICYCLIC PARP1 INHIBITORS AND THEIR USES
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer
CN121079090A (zh) 2023-05-11 2025-12-05 阿斯利康(瑞典)有限公司 用于治疗癌症的parp1抑制剂和选择性雌激素降解剂的组合
WO2025078276A1 (en) 2023-10-09 2025-04-17 Nerviano Medical Sciences S.R.L. Combination of a parp-1 selective inhibitor and temozolimde and its use in the treatment of glioma
WO2025090418A1 (en) 2023-10-23 2025-05-01 Gilead Sciences, Inc. Parp1 inhibitors and uses thereof
WO2025108423A1 (zh) * 2023-11-24 2025-05-30 杭州领业医药科技有限公司 一种选择性parp-1抑制剂的晶型及其制备方法和用途
WO2025148856A1 (zh) * 2024-01-10 2025-07-17 杭州领业医药科技有限公司 一种选择性parp-1抑制剂盐酸盐的晶型及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232842B2 (en) 2003-01-10 2007-06-19 Board Of Trustees Of The Leland Stanford Junior University Kinase inhibitors and associated pharmaceutical compositions and methods of use
WO2007047646A2 (en) 2005-10-14 2007-04-26 Janssen Pharmaceutica, N.V. Substituted dihydro-isoindolones useful in treating kinase disorders
JP4929834B2 (ja) * 2006-05-18 2012-05-09 富士通セミコンダクター株式会社 ラッチ回路
US8143284B2 (en) * 2006-10-05 2012-03-27 Abbott Laboratories Poly(ADP-ribose)polymerase inhibitors
CA2623257A1 (en) * 2008-02-29 2009-08-29 Scanimetrics Inc. Method and apparatus for interrogating an electronic component
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物
EP2454237B1 (en) * 2009-07-14 2016-09-07 Nerviano Medical Sciences S.r.l. 3-oxo-2,3,-dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition
ES2759751T3 (es) 2009-07-14 2020-05-12 Nerviano Medical Sciences Srl 3-oxo-2,3-dihidro-1H-isoindol-4-carboxamidas
US10385018B2 (en) 2012-10-26 2019-08-20 Nerviano Medical Sciences S.R.L. 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors

Also Published As

Publication number Publication date
US11420940B2 (en) 2022-08-23
BR112015009130A2 (pt) 2017-07-04
US20200407314A1 (en) 2020-12-31
EP2912032B1 (en) 2020-05-27
CN104768948A (zh) 2015-07-08
EP2912032A1 (en) 2015-09-02
JP2015535228A (ja) 2015-12-10
AU2013336725B2 (en) 2018-02-22
AU2013336725A1 (en) 2015-06-11
CA2889581C (en) 2021-06-29
JP6314147B2 (ja) 2018-04-18
US20150274662A1 (en) 2015-10-01
WO2014064149A1 (en) 2014-05-01
US20190330151A1 (en) 2019-10-31
US11773064B2 (en) 2023-10-03
BR112015009130B1 (pt) 2020-09-24
MX2015005245A (es) 2015-07-14
HK1212331A1 (en) 2016-06-10
HUE051078T2 (hu) 2021-03-01
US10385018B2 (en) 2019-08-20
EA201590820A1 (ru) 2015-11-30
CA2889581A1 (en) 2014-05-01
DK2912032T3 (da) 2020-08-31
US20220363636A1 (en) 2022-11-17
ES2813530T3 (es) 2021-03-24
SI2912032T1 (sl) 2020-11-30
KR102221199B1 (ko) 2021-03-04
PT2912032T (pt) 2020-09-03
EA028506B1 (ru) 2017-11-30
US10800739B2 (en) 2020-10-13
PL2912032T3 (pl) 2020-11-16
CN104768948B (zh) 2018-11-27
KR20150074174A (ko) 2015-07-01
MX367425B (es) 2019-08-21

Similar Documents

Publication Publication Date Title
CL2015001020A1 (es) Compuestos derivados de 4-carboxamido-isoindolinona, inhibidores selectivos de parp-1; proceso de preparacion; composicion farmaceutica; un metodo in vitro; un producto; y su uso como medicamento con actividad antineoplasica
AP4028A (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
EP2743269A4 (en) PIM KINASEHEMMER, PROCESS FOR ITS PREPARATION AND ITS USE IN THE DRUG MANUFACTURING
IL230874A (en) History of dihydroquinoline-2-on-egg scallops, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
BR112013030472A2 (pt) formulação farmacêutica, artigo de fabricação e método
ZA201501541B (en) Supported catalyst and active form thereof, and preparation method and use thereof
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
AP2015008599A0 (en) Pharmaceutical composition for treating headache, and preparation method thereof
HUE060093T2 (hu) Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL227404A0 (en) Pyrimidine history, their preparation and pharmaceutical preparations containing them
IL239146A0 (en) Aminocyclobutane derivatives, methods for their preparation and their use as drugs
PH12014502834A1 (en) Pharmaceutical form for extended release of active substances
ZA201309559B (en) Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof
EP2889287A4 (en) DOLASTATIN-10-DERIVAT, PROCESS FOR THE PREPARATION THEREOF AND ANTI-CANCER MEDICAMENT THEREWITH
IL237688A0 (en) A syringe containing a preparation, in particular a pharmaceutical preparation containing immunoglobulins, a method for its production and use
EP2875814A4 (en) LIQUID COMPOSITION CONTAINING TAXANE ACTIVE INGREDIENT, MANUFACTURING METHOD THEREOF, AND LIQUID MEDICINAL PREPARATION
IL219872A (en) Quinazoline derivatives, their uses, their preparation, and their medications
IL236562A0 (en) A pharmaceutical preparation with an improved flow capacity, a medical agent, and a method for its production and use
PL399613A1 (pl) Pochodne estrów diarylowych kwasów 1-aminoalkanofosfonowych, sposób wytwarzania pochodnych estrów diarylowych kwasów 1-aminoalkanofosfonowych oraz ich zastosowanie
PL2497774T3 (pl) Pochodne dihydro-oksazolobenzodiazepinonu, sposoby ich wytwarzania i kompozycje farmaceutyczne zawierające te związki
HRP20180781T1 (hr) Farmaceutski pripravak koji sadržava lidipidipin i proces pripreme
IL234614B (en) Pharmaceutical composition and preparation method thereof
CO6930059A1 (es) Formulaciones farmacéuticas y proceso de producción de formulaciones farmacéuticas
PT2802558T (pt) Compostos com atividade antibacteriana, processo para a sua preparação, e composições farmacêuticas compreendendo os mesmos